pleckstrin homology and RUN domain containing M1 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored PLEKHM1P1 profile across patient tissues and cancer cell-line models. PLEKHM1P1 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PLEKHM1P1 is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, PLEKHM1P1 RNA expression shows 19,818 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where PLEKHM1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLEKHM1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLEKHM1P1 survival associations across molecular data types. PLEKHM1P1 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLEKHM1P1 RNA expression–survival associations across cancer types. High PLEKHM1P1 expression shows unfavorable associations in KIRC, LGG, COAD and PRAD, but favorable associations in BLCA and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PLEKHM1P1 RNA expression.
This table summarizes PLEKHM1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for PLEKHM1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLEKHM1P1 shows lower tumor expression in KICH and BRCA and higher tumor expression in COAD, LIHC, STAD and CHOL. The KICH box plot shows higher PLEKHM1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.918, t-test p < 0.001).
This table shows molecular features associated with PLEKHM1P1 in patient tissues and cancer cell lines. In patient samples, PLEKHM1P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PLEKHM1P1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma.
